About this trial
Every year, 100 boys are born in the UK with a rare muscle disease called Duchenne muscular dystrophy. These boys cannot make an important muscle protein called dystrophin. They become weaker as they get older and lose the ability to walk as teenagers. This is a life-limiting condition. There is no cure, but medicines are being made that could help these boys make dystrophin. These medicines are most likely to work best in toddlers, before their muscles become damaged.
There is no way of testing these medicines in children under four. In older children, it is possible to measure how well and how quickly a child can do movements like sitting up, standing up, and running. Unfortunately, these tests are not suitable for toddlers as they often struggle to listen and do what they are asked to do. Tiredness and mood can also affect their scores. Luckily, there is a new way of testing how well children move. They can wear special watch-like devices on their ankles that record information about their steps as they go about their normal lives. This is a good way of testing how well a child walks. It is now used to test medicines in children over four years old. Our aim is to test whether this device works well in children under four.
This study will invite 30 boys with DMD (and their parent/caregiver) and 30 boys without DMD aged 1-3 years old from across the country to join the study. There are no hospital visits. Children will receive the watch-like devices to wear for three blocks of 28-days over six months during their normal daily activities. At the start and end of the study, a physiotherapist will visit the homes of boys with DMD. They will check their movements using other tests. The investigators will find out 1) if young boys are happy to wear the device, 2) how it compares to other tests, and 3) if it can detect changes in walking ability.
This study could give us a way to test medicines in younger children. Wearable devices could cut down the travel and stress of tests for boys and their families. Children with learning or behavioural difficulties, and children living far from research centres could now also take part in studies of new medicines. This study could bring us a step closer to treating this life-limiting disease.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male
Aged 1-3 years old
Ambulant (walking 10m independently)
Genetically confirmed diagnosis of DMD
Disqualifiers
Limb surgery/trauma (within 6 months)
Significant comorbid chronic or acute conditions affecting motor function (within 3 weeks)
Prematurity (born <37 weeks' gestation)
Oral corticosteroids to treat DMD (before enrolment)
Trial population
Participants with DMD and healthy controls within the UK, identified via advertisements and through clinic lists.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
To assess the within-patient variability in SV95C using the Syde device to remotely assess motor function in boys with DMD under the age of four.
Within-patient variability in SV95C will be measured over 2 periods of 28 days using the Syde device on both ankles.
To assess the test-retest reliability of the Syde device to remotely assess motor function in boys with DMD under the age of four.
Test-retest reliability will be measured using intra-class correlation coefficient (ICC) of consecutive measurements of SV95C.
To assess compliance with the Syde device in boys with DMD under the age of four.
Compliance will be measured by percentage of participants completing minimum recording period of the Syde device.
To assess the acceptability of using the Syde device in boys with DMD under the age of four.
Acceptability will be measured using the device acceptability questionnaire for Syde device.
Secondary outcomes
To investigate whether SV95C recordings from the Syde device can distinguish boys with DMD from controls.
Construct validity will be measured by the difference in SV95C between DMD and controls using the Syde device.
To assess correlation between SV95C as measure by the Syde device and other motor assessment and parent-reported outcomes.
Convergent validity will by measure by correlation between SV95C, NSAA, gross motor domain of Bayley Scale of Infant Development-4, and parent-reported outcomes.
To assess impact of cognitive, behavioural, and language impairment on SV95C and other motor assessments.
Association between cognitive, behavioural, and language domains of Bayley Scale of Infant Development-4 and NSAA and SV95C.
To determine the sensitivity of SV95C to change.
6-month change in SV95C in boys with DMD compared to controls.
Other outcomes
To assess the reliability of other outcome measures from Syde device.
Metrics derived from the Syde device such as median stride velocity (SV50C), stair-climbing velocity.
To investigate the economic impact of DMD diagnosis, care and assessments on families of children under four for a future health economic analysis.
Health economic data collected from questionnaires.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.